MARKET

THOR

THOR

Synthorx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

67.82
+0.11
+0.16%
Opening 12:39 12/10 EST
OPEN
67.50
PREV CLOSE
67.71
HIGH
68.05
LOW
67.50
VOLUME
787.69K
TURNOVER
--
52 WEEK HIGH
68.05
52 WEEK LOW
11.00
MARKET CAP
1.86B
P/E (TTM)
-35.1636
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of THOR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

THOR News

  • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of SYNTHORX, INC. - THOR
  • PR Newswire.43m ago
  • Company News for Dec 10, 2019
  • Zacks.3h ago
  • Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research
  • Zacks.3h ago
  • Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms
  • Zacks.4h ago

More

Industry

Biotechnology & Medical Research
+0.70%
Pharmaceuticals & Medical Research
+0.71%

Hot Stocks

Name
Price
%Change

About THOR

Synthorx, Inc. is a biopharmaceutical company. The Company is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. Its platform technology expands the genetic code by adding a new deoxyribonucleic acid (DNA) base pair and is designed to create optimized biologics, which is referred as Synthorins. The Company’s lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer (NK), cells without causing vascular leak syndrome (VLS), observed with IL-2 (aldesleukin). Its cytokine Synthorin programs, including IL-2, IL-10 and IL-15 for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.
More

Webull offers Synthorx Inc (THOR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.